VectorY Therapeutics
PrivateLast Round
Series A
Nov 11, 2026
Total Funding Raised
$259.5M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
VectorY Therapeutics operates in Healthcare & Life Sciences and is based in Amsterdam. Its latest recorded funding round was a Series A round in November 2026.
VectorY Therapeutics is a biotechnology company that develops vectorized antibody therapies for neurodegenerative diseases including ALS, Huntington's, and Parkinson's disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VectorY Therapeutics Comparables
Compare VectorY Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AviadoBio | 86% | |
| Capsida Biotherapeutics | 83% | |
| Latus Bio | 83% |
For institutional investors. Book with your work email.
VectorY Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 11, 2026 | ||||
| Series A | Nov 13, 2023 | ||||
| Seed | Jun 15, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
VectorY Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series A |
| Forbion | Series A, Seed |
| Invest-NL | Series A |
| European Investment Bank Group | Series A |
| ALS Investment Fund | Series A |
| Angelini Ventures | Series A |
| BioGeneration Ventures | Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 11, 2026
$84M round with participation from EQT Life Sciences and Forbion.
- Aug 21, 2026
Monthly visitors increased 43% MoM, reaching 6.6K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresNov 12, 2026
vectorytx.com is bringing Regina Hodits onto its board as an observer.
- is_developingSep 30, 2026
vectorytx.com is developing VTx-003 for Huntington's disease.
- is_developingSep 30, 2026
vectorytx.com is developing VTx-002 for ALS, along with VTx-003 for Huntington's disease, VTx-004 for frontotemporal dementia, and VTx-005 for Alzheimer's disease.
- is_developingSep 30, 2026
vectorytx.com is developing VTx-004 for frontotemporal dementia.
For institutional investors. Book with your work email.
VectorY Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about VectorY Therapeutics's valuation, stock price, and market status.
Is VectorY Therapeutics a public or private company?
VectorY Therapeutics is a private company.
What is the current stock price of VectorY Therapeutics?
VectorY Therapeutics is a private company, so its shares have no public market price. Caplight tracks VectorY Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is VectorY Therapeutics worth (valuation)?
Valuation information for VectorY Therapeutics is not publicly available.
Can I buy VectorY Therapeutics stock?
VectorY Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was VectorY Therapeutics's last funding round?
VectorY Therapeutics's most recent funding round was Series A on November 11, 2026.
Who are the main investors in VectorY Therapeutics?
Key investors in VectorY Therapeutics include EQT Life Sciences, Forbion.
Will VectorY Therapeutics IPO soon?
No public IPO plans have been announced for VectorY Therapeutics.
How can I track VectorY Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in VectorY Therapeutics's shares on secondary markets.